TAKEDA PHARMACEUTICAL COMPANY LIMITED Company Takeda Pharmaceutical Company Limited Deutsche Boerse AG
Equities
TKDA
US8740602052
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.6 EUR | -4.13% |
|
-4.92% | -7.94% |
Business Summary
- sale of drugs and consumer care products;
- services.
Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Number of employees: 49,095
Sales per Business
| JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Gastroenterology - Entyvio
17.4
%
| 521,778 | 14.6 % | 702,744 | 17.4 % | +34.68% |
Plasma-derived Therapies - Immunoglobulin
13.0
%
| 385,864 | 10.8 % | 522,211 | 13.0 % | +35.34% |
Neuroscience - Vyvanse/Elvanse
11.4
%
| 327,052 | 9.2 % | 459,289 | 11.4 % | +40.43% |
Other - Others
9.1
%
| 515,164 | 14.4 % | 364,968 | 9.1 % | -29.15% |
Rare Genetic Diseases and Others - Tacxiro
3.8
%
| - | - | 151,800 | 3.8 % | - |
Plasma-derived Therapies - Albumin
3.0
%
| 90,035 | 2.5 % | 121,446 | 3.0 % | +34.89% |
Rare Blood Disease - advertise
2.9
%
| 118,491 | 3.3 % | 118,188 | 2.9 % | -0.26% |
Oncology - Leuplin/Enantone
2.8
%
| 106,459 | 3.0 % | 111,311 | 2.8 % | +4.56% |
Gastroenterology - Takecab-f
2.7
%
| 102,397 | 2.9 % | 108,719 | 2.7 % | +6.17% |
Neuroscience - Trintelix
2.5
%
| 82,315 | 2.3 % | 100,081 | 2.5 % | +21.58% |
Gastroenterology - Gattex/Revestive
2.3
%
| 75,751 | 2.1 % | 93,076 | 2.3 % | +22.87% |
Oncology - Ninlaro
2.3
%
| 91,203 | 2.6 % | 92,691 | 2.3 % | +1.63% |
Rare Genetic Diseases and Others - Ella Place
2.1
%
| 73,119 | 2.0 % | 85,321 | 2.1 % | +16.69% |
Oncology - Adcetris
2.1
%
| 69,190 | 1.9 % | 83,937 | 2.1 % | +21.31% |
Neuroscience - Others
1.9
%
| 72,926 | 2.0 % | 78,341 | 1.9 % | +7.43% |
Other - Azilva
1.8
%
| 76,297 | 2.1 % | 72,897 | 1.8 % | -4.46% |
Gastroenterology - Others
1.8
%
| 82,877 | 2.3 % | 72,388 | 1.8 % | -12.66% |
Gastroenterology - Dexilant
1.7
%
| 50,763 | 1.4 % | 69,371 | 1.7 % | +36.66% |
Rare Genetic Diseases and Others - Replagal
1.7
%
| 51,714 | 1.4 % | 66,741 | 1.7 % | +29.06% |
Rare Blood Disease - Adynovate/Advynovi
1.7
%
| 60,726 | 1.7 % | 66,553 | 1.7 % | +9.60% |
Rare Genetic Diseases and Others - Others
1.4
%
| - | - | 55,989 | 1.4 % | - |
Oncology - Others
1.3
%
| 43,329 | 1.2 % | 51,551 | 1.3 % | +18.98% |
Rare Genetic Diseases and Others - Biprib
1.2
%
| 42,408 | 1.2 % | 48,372 | 1.2 % | +14.06% |
Oncology - Iclusig
1.2
%
| 34,860 | 1.0 % | 47,206 | 1.2 % | +35.42% |
Rare Blood Disease - Other
1.2
%
| 53,013 | 1.5 % | 46,367 | 1.2 % | -12.54% |
Gastroenterology - Pantoloc/Controloc
1.1
%
| 40,275 | 1.1 % | 45,518 | 1.1 % | +13.02% |
Rare Blood Disease - Fiber
1.0
%
| 39,162 | 1.1 % | 41,268 | 1.0 % | +5.38% |
Plasma - Derived Immune Disease Treatment - Other
0.9
%
| 31,052 | 0.9 % | 34,786 | 0.9 % | +12.02% |
Oncology - Velcade
0.7
%
| 110,046 | 3.1 % | 27,759 | 0.7 % | -74.78% |
Oncology - Arumbrig
0.5
%
| 13,644 | 0.4 % | 20,556 | 0.5 % | +50.66% |
Rare Blood Disease - Hemofil/Immunate/Immunine
0.5
%
| - | - | 19,581 | 0.5 % | - |
Other - Rotrigger
0.4
%
| 32,690 | 0.9 % | 16,732 | 0.4 % | -48.82% |
Rare Hematology - Recombinate
0.3
%
| 12,297 | 0.3 % | 12,762 | 0.3 % | +3.78% |
Rare Genetic Diseases and Others - Livetencity
0.3
%
| - | - | 10,501 | 0.3 % | - |
Oncology - Exkivity
0.1
%
| - | - | 3,732 | 0.1 % | - |
Gastroenterology - Alofisel
0.1
%
| 1,843 | 0.1 % | 2,725 | 0.1 % | +47.86% |
Sales per region
| JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
United States
52.2
%
| 1,714,421 | 48.0 % | 2,103,772 | 52.2 % | +22.71% |
Europe and Canada
20.9
%
| 739,168 | 20.7 % | 842,668 | 20.9 % | +14.00% |
Japan
12.7
%
| 658,983 | 18.5 % | 512,043 | 12.7 % | -22.30% |
Asia
5.6
%
| 196,964 | 5.5 % | 225,007 | 5.6 % | +14.24% |
Latin America
4.0
%
| 128,467 | 3.6 % | 160,375 | 4.0 % | +24.84% |
Other
2.4
%
| 68,945 | 1.9 % | 95,182 | 2.4 % | +38.05% |
Russia / Commonwealth of Independent States
2.2
%
| 62,057 | 1.7 % | 88,431 | 2.2 % | +42.50% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 01/14/01 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 01/22/01 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 01/12/01 |
| Chief Tech/Sci/R&D Officer | 69 | 01/15/01 | |
Andrew Plump
CTO | Chief Tech/Sci/R&D Officer | 58 | 01/15/01 |
Norimasa Takeda
CMP | Compliance Officer | - | - |
| Director/Board Member | 53 | 01/15/01 | |
Haruhiko Hirate
IRO | Public Communications Contact | - | - |
Takashi Okubo
IRO | Public Communications Contact | - | - |
| Investor Relations Contact | - | 01/11/01 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 71 | 01/16/01 | |
Ian Clark
BRD | Director/Board Member | 62 | 01/19/01 |
Steven Gillis
BRD | Director/Board Member | 71 | 01/19/01 |
John Maraganore
BRD | Director/Board Member | 60 | 01/22/01 |
Emiko Higashi
BRD | Director/Board Member | 64 | 01/16/01 |
Michel Orsinger
BRD | Director/Board Member | 66 | 01/16/01 |
Christophe Weber
CEO | Chief Executive Officer | 57 | 01/14/01 |
| Director/Board Member | 53 | 01/15/01 | |
Kimberly Reed
BRD | Director/Board Member | 53 | 01/22/01 |
Miki Tsusaka
BRD | Director/Board Member | 61 | 01/23/01 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 0 | 1,582,418,725 | 1,568,501,201 ( 99.12 %) | 13,405,261 ( 0.8471 %) | 99.12 % |
Holdings
| Name | Equities | % | Valuation |
|---|---|---|---|
| 7,511,300 | 0.47% | 199,463,248 $ | |
HILLEVAX, INC. 13.52% | 6,724,000 | 13.52% | 81,629,360 $ |
DENALI THERAPEUTICS INC. 2.96% | 4,214,559 | 2.96% | 78,222,215 $ |
| 2,204,000 | 7.21% | 33,085,588 $ | |
OVID THERAPEUTICS INC. 12.38% | 8,781,996 | 12.38% | 26,872,908 $ |
| 2,790,480 | 4.77% | 26,286,322 $ | |
WAVE LIFE SCIENCES LTD. 0.90% | 1,096,892 | 0.90% | 6,778,793 $ |
NOILE-IMMUNE BIOTECH INC. 18.76% | 8,119,800 | 18.76% | 6,768,828 $ |
Company contact information
Takeda Pharmaceutical Co., Ltd.
4-1-1 Dosho-machi Chuo-Ku
540-8645, Osaka
+81 3 3278 2111
http://www.takeda.co.jp
Group companies
| Name | Category and Sector |
|---|---|
Takeda A/S
 Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. |
Financial Conglomerates
|
Takeda Pharmaceuticals U.S.A., Inc.
 Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. |
Pharmaceuticals: Major
|
Takeda Pharmaceuticals International AG
 Takeda Pharmaceuticals International AG Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals International GmbH develops, manufactures, and distributes pharmaceutical products. It offers medicines in therapeutic areas, such as, cardiovascular and metabolic, oncology, central nervous system, respiratory and immunology, general medicine, and vaccines. The firm also provides packaging, development, contract manufacturing and quality control services. Takeda Pharmaceuticals International was founded in 1874 and is headquartered in Zurich, Switzerland. |
Pharmaceuticals: Major
|
Takeda Austria GmbH
 Takeda Austria GmbH Miscellaneous Commercial ServicesCommercial Services Part of Takeda Pharmaceutical Co., Ltd., Takeda Austria GmbH engages in research and development of pharmaceutical products. The company is based in Linz, Austria. Kirsten Detrick has been the CEO of the Austrian company since 2016. |
Miscellaneous Commercial Services
|
Takeda GmbH
 Takeda GmbH Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Takeda GmbH is a German pharmaceutical company that manufactures pharmaceutical products. The company is based in Konstanz, Germany. The CEOs are Wolfgang Eck, Uwe Hoffmeister, Roland Kurney. The company was founded in 1873. |
Pharmaceuticals: Major
|
Takeda Manufacturing Austria AG
 Takeda Manufacturing Austria AG Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Takeda Manufacturing Austria AG manufactures and supplies vital medicines and medical devices. The company is based in Vienna, Austria. |
Pharmaceuticals: Major
|
Shire Ireland Finance Trading Ltd.
| |
Shire Biotech India Pvt Ltd.
| |
Shire Biotech UK Holdings Ltd.
 Shire Biotech UK Holdings Ltd. Financial ConglomeratesFinance Part of Takeda Pharmaceutical Co., Ltd., Shire Biotech UK Holdings Ltd. is an investment holding company. Shire Biotech UK Holdings Ltd. is based in London, UK. Founded in 2017, Shire Biotech UK Holdings functions as an investment holding company. |
Financial Conglomerates
|
Sector
Sales per Business
Sales per region
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +52.93% | 803B | |
| +40.98% | 631B | |
| -7.08% | 351B | |
| +17.40% | 324B | |
| +10.58% | 303B | |
| +16.42% | 243B | |
| +2.17% | 228B | |
| +10.66% | 217B | |
| +6.24% | 164B |
- Stock Market
- Equities
- 4502 Stock
- TKDA Stock
- Company Takeda Pharmaceutical Company Limited
